Teams reactively managed trials across scattered systems. AI now integrates data to predict bottlenecks and recommend interventions.
A global biopharmaceutical leader faces the high stakes of Phase III clinical trials, where median costs range from $19 million to over $100 million per trial.
Complex logistics across partners and clinical sites created fragmented workflows, forcing teams to manage trials reactively rather than proactively....
“At Bristol Myers Squibb, we’re using technologies that include AI and machine learning to optimize development timelines and reimagine what’s possible in drug development.”
Biopharmaceutical company developing treatments for serious diseases.
Related implementations across industries and use cases
Writers spent weeks sifting through data to draft reports. AI now generates a 14-section first draft in minutes for review.
Data friction slowed trial design. A decentralized platform now lets 20+ teams access data 10x faster and deploy tools 7x faster.
Selecting trial sites took months of manual data collection. AI now generates lists in 24 hours, cutting activation cycles by 10%.
Silos forced teams to manually chase data. Now, AI agents identify adverse events in seconds, eliminating weeks of cross-referencing.
Attorneys juggled fragmented tools to search 50,000 cases. An AI orchestrator now routes queries to sub-agents in a single chat.
Lab supply orders were handwritten in notebooks. Digital ordering now takes seconds, saving 30,000 hours for research annually.
Experts spent 15 minutes pulling data from scattered systems. Natural language prompts now generate detailed reports instantly.